Immunotherapy Side Effects May Be More Common Than Thought

TUESDAY, Nov. 20, 2018 -- Adverse events for immune checkpoint inhibitors used to treat non-small cell lung cancer (NSCLC) may be more common in real-world settings than reported in the clinical trials that led to U.S. Food and Drug Administration...

https://ift.tt/2FAWPwL